Treating Leukoencephalopathy With Calcifications and Cysts With Bevacizumab

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041205

Enrollment

Unknown

Registered

2020-12-22

Start date

2020-12-25

Completion date

Unknown

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inherited Leukoencepalopathy

Interventions

1:bevacizumab

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.The diagnosis is established by genetic testing showing SNORD118 pathological variant or brain biopsy. 2.Normal function of heart,lung,liver and kidney. 3.Informed consent obtained.

Exclusion criteria

Exclusion criteria: 1.Uncertain diagnosis of Leukoencephalopathy With Calcifications and Cysts. 2.Significant dysfunction of heart,lung,liver and kidney.

Design outcomes

Primary

Measure	Time frame
Activity of Daily Living Scale;Brain MRI;	—

Countries

China

Contacts

Public ContactWang Kang

The First Affiliated Hospital, School of Medicine, Zhejiang University

fcwangk1@zju.edu.cn+86 13588086498

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026